Net income
-1.4 million USD
2018-10-01 – 2019-09-30
Fundies. English
IASO BioMed, Inc.
EDGAR14 filing records in this dataset, filed from 2016-12-14 to 2019-11-19. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 3.39 thousand USD Source
Exact value
3394 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 37.2 million shares Source
Exact value
37248744 shares
Reported share-count change
3.61% · 1.3 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-186 thousand USD
2018-10-01 – 2019-09-30
Exact inputs and evidence
- Operating cash flow: -291707 USD · 2018-01-01 – 2018-12-31 Source
- Operating cash flow: -254249 USD · 2018-01-01 – 2018-09-30 Source
- Operating cash flow: -64571 USD · 2019-01-01 – 2019-03-31 Source
- Operating cash flow: -131645 USD · 2019-01-01 – 2019-06-30 Source
- Operating cash flow: -64571 USD · 2019-01-01 – 2019-03-31 Source
- Operating cash flow: -148351 USD · 2019-01-01 – 2019-09-30 Source
- Operating cash flow: -131645 USD · 2019-01-01 – 2019-06-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2019-11-19.
Financial data available through: 2018-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 3 of 11 periods available· newest 2018-12-31
- Net income: 3 of 11 periods available· newest 2018-12-31
- Operating cash flow: 3 of 11 periods available· newest 2018-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 3 of 11 periods available· newest 2018-12-31
- Total liabilities: 3 of 11 periods available· newest 2018-12-31
- Current assets: 3 of 11 periods available· newest 2018-12-31
- Current liabilities: 3 of 11 periods available· newest 2018-12-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2018-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 3 of 11 periods available· newest 2018-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 920,824Prior period
−USD 716,413
–
Current period
−USD 1.64 million
–
Exact inputs and evidence
-1637237 − -716413 = -920824 USD
-716413 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source-1637237 USD · 2018-01-01 – 2018-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 29,707Prior period
−USD 262,000
–
Current period
−USD 291,707
–
Exact inputs and evidence
-291707 − -262000 = -29707 USD
-262000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source-291707 USD · 2018-01-01 – 2018-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | −USD 610,650 Exact valueExact value: -610650 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 300,122 Exact valueExact value: -300122 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2017-01-01 – 2017-12-31 | −USD 716,413 Exact valueExact value: -716413 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 262,000 Exact valueExact value: -262000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | −USD 1.64 million Exact valueExact value: -1637237 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 291,707 Exact valueExact value: -291707 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
14 filings · 429 latest values · 429 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001662907, 1662907, edgar:1662907, iaso
Also known as IASO BIOMED, INC., IASO BioMed, Inc.